PET/CT Evaluation of Brain Aβ and Metabolism in a Marmoset Model of Alzheimer's Disease Based on Tau Seeding

TL;DR

Researchers created a marmoset model of Alzheimer's by injecting tau, observing increased amyloid-beta and decreased brain metabolism, which could help in understanding and treating the disease.

Contribution

A novel marmoset model of sporadic Alzheimer's disease using tau seeding to accelerate AD-related phenotypes.

Findings

11C-PiB uptake increased and 18F-FDG decreased post-seeding, indicating Aβ accumulation and reduced metabolism.

Blood biomarkers showed a spike in total Tau after seeding, followed by a return to baseline.

Immunohistochemistry confirmed tau propagation from injection sites to other brain regions.

Abstract

Alzheimer's disease (AD) is the leading form of dementia, affecting 7 million Americans over age 65. AD is characterized by the accumulation of amyloid‐β (Aβ) plaques in the brain and the formation of neurofibrillary tangles (NFT) of hyperphosphorylated tau. Aβ and tau accumulate in the brain decades before cognitive decline. However, the relationship between Aβ and tau remains unclear. We hypothesized that injecting tau into the entorhinal cortex and hippocampus of aging marmosets would trigger NFT formation and propagation, accelerating impairments across various AD‐related sensory, motor, cognitive, and non‐cognitive phenotypes associated with disease progression.

Ten marmosets aged 65‐142 months (5F) received bilateral stereotactic injections of AAV‐P301LTau into the entorhinal cortex and hippocampus. A neuroimaging series consisting of anatomical and functional MRI along with PET/CT, using the radioligands 11C‐PiB to track Aβ and 18F‐FDG to monitor glucose metabolism, was employed at a pre‐seeding baseline and again at 6 and 12 months post‐seeding. The marmosets were fasted for two hours before the scans, and 11C‐PiB and 18F‐FDG were injected IV at an average dose of 18.5 MBq. Dynamic datasets were analyzed for standard uptake values (SUV) using PMOD v3.4. Statistical tests were conducted using GraphPad Prism 9. Cognitive, behavioral, and social assessments were conducted. Blood‐based biomarkers (Aβ40, Aβ42, GFAP, NFL, and total Tau) were measured using ELISA. In deceased marmosets (N = 3, 2F), immunohistochemistry for total Tau, 3RTau, 4RTau, and Thr231 was performed.

Whole brain 11C‐PiB uptake increased, and 18F‐FDG decreased between pre‐seeding and post‐seeding scans. Age‐ and sex‐matched non‐seeded marmosets also showed lower 11C‐PiB uptake than seeded marmosets, suggesting a rise in Aβ following tau seeding. Blood‐based biomarkers indicated an initial post‐seeding spike in total Tau and a return to baseline levels. IHC analysis confirmed the successful seeding and propagation of tau from the entorhinal cortex and hippocampus to the prefrontal and posterior regions of the brain cerebellum.

We established, characterized, and validated a marmoset model of sporadic AD based on seeding tau to accelerate the emergence of AD‐related phenotypes. These marmosets will be invaluable in translational research to elucidate the pathogenic mechanisms of AD and contribute to novel therapeutics for AD.